Identifying flaws in the GWAS datasets of a published Mendelian randomization study: complementary re-evaluation and suggestion for analytical refinements
Jia-Cheng Xiang and Yi-Fan Xiong share co-first authorship and contributed equally to this work.
Shao-Gang Wang and Qi-Dong Xia contributed equally to this work.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
To the editor,
In “Mendelian randomization and transcriptomic analysis reveal an inverse causal relationship between Alzheimer’s disease and cancer”, Zehua Dong and colleagues discovered a general protective effect of Alzheimer’s disease (AD) on cancer. However, after searching in a widely used GWAS database, IEU Open GWAS (https://gwas.mrcieu.ac.uk/) [1], we found several incorrect GWAS datasets were employed: ebi-a-GCST005921 [2] was used as exposure dataset for AD, which is actually “family history of AD”; furthermore, ukb-b-17001 and ukb-a-296 actually represent “ever had bowel cancer screening”, which were used as outcome datasets for bowel cancer (Fig. 1). Apparently, the authors used the incorrect GWAS datasets and did not explain for it. However, with a high heritability (60–80%), AD does have a strong correlation with AD family history [3]. We collated the recently published large AD GWAS dataset (ebi-a-GCST90027158) [4] and used Mendelian randomization (MR) to further investigate the relationship between AD and family history of AD (instrumental variables demonstrated in Additional file 2: Table S1, Additional file 3: Table S2). The results showed a significant bidirectional promoting causal relationship between them (Fig. 2A, Additional file 1: Figs. S1, S2). We suspected that both are driven by the same genetic variants and therefore conducted co-localization analyses in two genomic regions, including the regions near the lead SNP for ebi-a-GCST005921 and near PVRIG genetic locus (a risk gene for AD identified by the author). Within both gene regions, we discovered a very high posterior probability (100% and 99.14%) supporting Hypothesis 4 (H4), and two co-localized genetic loci (rs117310449 and rs6979218) were identified respectively (Fig. 2B, C, Table 1). Conclusively, to some extent, the family history of AD may be able to be used as a substitute for the onset of AD, but there are significant limitations that need to be discussed in the study. In addition, a large amount of GWAS datasets on AD disease have been shared in several public databases (IEU Open GWAS, GWAS Catalog), so there is no need to investigate the relationship between AD and cancer by using GWAS data on family history of AD. We suggest that the authors replace the research question in the paper with the relationship between AD family history and cancer, which is a very research-valuable question as well; and the relationship between AD and cancer needs to be further researched with the correct dataset.
Table 1
Results of the posterior probability obtained from co-localization analyses
Exposure
Outcome
nSNPs
Chr
Position
PP.H0.abf
PP.H1.abf
PP.H2.abf
PP.H3.abf
PP.H4.abf
Colocalized SNP
AD family history
(ebi-a-GCST005921)
Alzheimer's disease
(ebi-a-GCST90027158)
473
19
45411941 ± 100000 bp (around lead SNP: rs429358)
0.00%
0.00%
0.00%
0.00%
100.00%
rs117310449
247
7
99716871–99919113 bp (around PVRIG gene loci)
0.00%
0.04%
0.00%
0.81%
99.14%
rs6979218
PVRIG
(eqtl-a-ENSG00000213413)
AD family history
(ebi-a-GCST005921)
301
7
99719480 ± 100000 bp (around lead SNP: rs60458236)
0.00%
0.00%
0.57%
18.97%
80.46%
rs705867
Alzheimer's disease
(ebi-a-GCST90027158)
396
7
99719480 ± 100000 bp (around lead SNP: rs60458236)
0.00%
0.00%
0.00%
28.79%
71.21%
rs55796551
“PP.H0-4.abf” represents the posterior probability supporting the H0-4 hypotheses in co-localization analysis
×
×
Anzeige
Additionally, the authors extracted eQTL data of brain tissue and whole blood from the GTEX database and identified PVRIG as a risk gene for AD by co-localization analysis. We believe that the robustness of the proof process in this section needs to be improved: firstly, the authors performed the analysis using the Coloc R package and the web tool Sherlock, but only reported the log Bayes factor (LBF) without the posterior probabilities of each hypothesis for the co-localization analysis; secondly, co-localization analysis is mainly adopted to evaluate whether two traits are driven by the same genetic locus, which is insufficient to establish a causal link between them [5], whereas Mendelian randomization can establish a valid causal relationship, however, the authors identified PVRIG as a risk gene for AD only after co-localization; finally, the authors used only eQTL data from GTEX without external validation, thus the conclusions remain highly limited to some extent. Therefore, collecting the cis-eQTLs near the PVRIG gene from the eQTLGen database as the exposure (instrumental variables demonstrated in Additional file 4: Table S3), we performed Mendelian randomization analyses to explore the causal relationship between PVRIG and the two AD related traits. Interestingly, the MR results showed that PVRIG was a significant protective factor for both of the AD family history and AD (Fig. 3A, Additional file 1: Figs. S3, S4), contrary to the conclusions obtained by the authors. Reverse MR analysis have ruled out the existence of a reverse causal effect (Additional file 1: Fig. S5). We recommend that the authors perform MR analyses with data from the GTEX database as well. Furthermore, we performed co-localization analyses between PVRIG and the two AD related traits in the gene region near the lead SNP for PVRIG eQTL data. The results showed that the posterior probability supporting H4 was 80.46% between PVRIG and family history of AD, and 71.21% between PVRIG and AD; the co-localized SNPs were rs705867 and rs55796551, respectively (Fig. 3B, C, Table 1).
×
In conclusion, we identified some errors in the GWAS datasets used by the authors, which suggests that some of the conclusions have limitation and inaccuracy that require more attention; furthermore, we provided suggestions for the authors to improve analytical methodology and conducted some complementary analyses using data from other sources, which led to some opposite conclusions. Figure 4 summarized our complementary analyses. Although the conclusions of our analyses differ from part of the authors’, both of us identify a strong association between PVRIG and AD, and the cellular and molecular mechanisms between them deserve to be further investigated.
We declared that there is no conflict of interest.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Identifying flaws in the GWAS datasets of a published Mendelian randomization study: complementary re-evaluation and suggestion for analytical refinements
verfasst von
Jia-Cheng Xiang Yi-Fan Xiong Shao-Gang Wang Qi-Dong Xia
Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.
Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.
Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.
„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.